HedgeChatter

  • Home /
  • Tag Archives

PPHM

Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process Parameters That Lead to Consistent Product Quality at IBC’S Biopharmaceutical Development and Production Conferenc

[at noodls] – Solutions to Increase Lifetime of Purifications Resins to Decrease Production Costs; Successful Utilization of a Quality by Design (QbD) Approach to Identify Critical Process Parameters That Control Critical … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

February 26, 2013 Bystocknews , Comments Off on Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process Parameters That Lead to Consistent Product Quality at IBC’S Biopharmaceutical Development and Production Conferenc read more

Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

[at noodls] – TUSTIN, CA — (Marketwire) — 12/11/12 — Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that it has received a letter from The NASDAQ Stock Market LLC notifying the company that it has regained … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here […]

December 11, 2012 Bystocknews , Comments Off on Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement read more

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments

[at noodls] – Contract Manufacturing Revenue Expected to Exceed $18 Million for Fiscal Year 2013; Company Reaches Agreement With FDA on Pivotal Phase III Clinical Trial Design for Cotara; Multiple Bavituximab Clinical … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

December 10, 2012 Bystocknews , Comments Off on Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments read more

Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012

[at noodls] – TUSTIN, CA — (Marketwire) — 12/03/12 — Peregrine Pharmaceuticals (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

December 3, 2012 Bystocknews , Comments Off on Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012 read more

Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ

[at noodls] – TUSTIN, CA — (Marketwire) — 11/14/12 — Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboard […]

November 14, 2012 Bystocknews , Comments Off on Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ read more

Peregrine Pharmaceuticals Provides Update on Corporate Activities

[at noodls] – Company Replaces Prior Loan Facility With Over $14 Million in Financing Proceeds Received Since September 27th; Growing Contract Manufacturing Business Remains on Track for Record Revenue Year; Multiple … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboard […]

October 17, 2012 Bystocknews , Comments Off on Peregrine Pharmaceuticals Provides Update on Corporate Activities read more

PropThink: PPHM’s Clandestine Capital Raise Provides Great Exit Opportunity; Sell Into Strength

[ACN Newswire] – By David MoskowitzIn a move of self-preservation, Peregrine Pharmaceuticals (NASDAQ:PPHM) announced Wednesday that it raised $14.3 million in gross proceeds through an ATM (At The Market) agreement with … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboard […]

October 17, 2012 Bystocknews , Comments Off on PropThink: PPHM’s Clandestine Capital Raise Provides Great Exit Opportunity; Sell Into Strength read more

PropThink: Peregrine Shares Continue to Bleed, Sticking Around Could Hurt Worse

[ACN Newswire] – By David MoskowitzPeregrine Pharmaceuticals (NASDAQ:PPHM) opened down in early trading, as investors are still getting over the shock of the favorable clinical trial results for bavituximab reported last … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboard […]

October 1, 2012 Bystocknews , Comments Off on PropThink: Peregrine Shares Continue to Bleed, Sticking Around Could Hurt Worse read more

PropThink: Yep, PPHM Likely To Go Sub-$1.00 Again

[ACN Newswire] – By David MoskowitzPeregrine Pharmaceuticals (NASDAQ:PPHM) announced more bad news Thursday, after receiving a default notice from lender, Oxford Finance, on Monday. The default on the loan was triggered … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboard […]

September 27, 2012 Bystocknews , Comments Off on PropThink: Yep, PPHM Likely To Go Sub-$1.00 Again read more

Peregrine Pharmaceuticals Announces That It Has Discovered Major Discrepancies in Treatment Group Coding by an Independent Third-Party Vendor Responsible for Distribution of Blinded Investigational Product Used in Its Bavituximab Phase II S

[at noodls] – The Company Is Currently Conducting a Detailed Review, Including Assessing Its Impact on Overall Trial Results; Investors Should Not Rely on Previously Reported Clinical Data Disclosed From This Phase … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboard […]

September 24, 2012 Bystocknews , Comments Off on Peregrine Pharmaceuticals Announces That It Has Discovered Major Discrepancies in Treatment Group Coding by an Independent Third-Party Vendor Responsible for Distribution of Blinded Investigational Product Used in Its Bavituximab Phase II S read more